In addition, Bobo has executive responsibility for key heart failure initiatives as well as the U.S. Bobo, Jr., has been corporate vice president since 2007 and is currently responsible for the company’s corporate strategy and corporate development functions. He has dual master’s degrees in science and business from Universities of Marseille, France.ĭonald E. Prior to joining Edwards, Zovighian held roles with increasing levels of responsibility at Johnson & Johnson (J&J) for nearly 20 years, including regional leadership outside of the United States and worldwide president of one of the company’s divisions. Zovighian blends a global mindset and a team-based approach to leadership with his strengths in strategy development, the innovation and adoption of disruptive technologies that elevate the standard of care, and the establishment of trusted partnerships. In his nearly 30-year career in medical technology, Zovighian spent 12 years leading global businesses across two world-class companies, during which time he lived in several countries and led teams in different locations. He later served as corporate vice president of the surgical business from 2016 until he began leading TMTT. Zovighian joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Structural Heart business, Edwards’ foundational organization dedicated to innovating surgical heart valve therapies. As the leader for TMTT, Zovighian established a global organization focused on developing and delivering a portfolio of therapies designed to change the standard of care for mitral and tricuspid patients. Prior to this leadership transition, Zovighian served since January 2018 as corporate vice president responsible for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business. In his role as CEO, Zovighian is focused on fostering and maintaining the unique culture of Edwards, supporting the career development of the company’s global employees and establishing trusted partnerships to advance innovative therapies for patients, addressing unmet patient needs and transforming care. In his time as president, he worked alongside non-executive chairman and former CEO Mike Mussallem in engagement with Edwards’ Board of Directors, executive leadership team, worldwide employees and other stakeholders to further Edwards’ patient-focused innovation strategy. Zovighian is CEO and on the Board of Directors of Edwards Lifesciences, after serving as president since January 2023.
0 kommentar(er)
